November 6, 2026 | 3 min read
A landmark study has challenged the conventional wisdom surrounding the diagnosis of peanut allergies in infants. According to new research published in the Journal of Allergy and Clinical Immunology: In Practice, more than one-third of infants previously labeled as "peanut-allergic" based on standard clinical assessments were found to be non-allergic when subjected to the gold-standard diagnostic test.
The findings, led by Dr. Kirsten Perrett of the Murdoch Children’s Research Institute at the Royal Children’s Hospital in Melbourne, suggest that the current reliance on biomarkers and reported medical history is frequently leading to misdiagnosis. This discovery has profound implications for how pediatricians approach food allergies in the first year of life, potentially sparing families from years of unnecessary dietary restrictions and anxiety.
The Core Findings: A Surprising Rate of Misdiagnosis
In the medical community, the standard procedure for diagnosing a peanut allergy in infants has long been straightforward: if a child displays an allergic reaction after peanut exposure and returns a positive result on a skin prick test (SPT) or a specific Immunoglobulin E (IgE) blood test, a diagnosis is made. These children are then typically placed on strict avoidance diets.
However, Dr. Perrett’s team found that this protocol is far from infallible. In a cohort of infants who had reacted to peanut before their first birthday, 34.8% tested negative during an oral food challenge (OFC)—the most definitive test for confirming an allergy. This means that more than one in three infants diagnosed through standard clinical markers were actually able to tolerate peanuts safely.
"The rate was far higher than expected," Dr. Perrett noted. The study suggests that many of these infants may have experienced a transient immune response that resolved on its own within a short period—often within six months of the initial reaction—or that their initial symptoms did not represent a true, persistent allergy.
Chronology of the ADAPT Program
The research was conducted under the umbrella of the Allergy Development to an Accelerated Pathway to Tolerance (ADAPT) program, a collaborative initiative involving 10 major pediatric hospitals across five Australian states. The ADAPT program was designed to create the first standardized, nationwide model of care for managing food allergies in infants.
1. Enrollment Criteria
The study enrolled infants who met two primary criteria:
- A documented history of an IgE-mediated allergic reaction to peanuts before reaching 12 months of age.
- Evidence of sensitization, defined as a skin prick test wheal of at least 3 mm or a peanut-specific IgE or Ara h 2-specific IgE level of at least 0.35 kUA/L.
2. Clinical Evaluation
Following the initial screening, the infants were categorized based on the severity of their initial reaction. Those who had experienced severe anaphylaxis (Consortium for Food Allergy Research grade 3) were eligible to proceed directly to oral immunotherapy (OIT). However, to better understand the nature of these reactions, a subset of these infants also underwent an OFC.
3. The Oral Food Challenge (OFC)
For infants with milder reactions (grades 1 or 2), an OFC was mandatory. The challenge served a dual purpose: confirming the allergy diagnosis and determining the specific reaction threshold to calibrate the starting dose for OIT. The challenges were performed using commercially available peanut flour (PB2) under strict medical supervision.
The median age for the OFC was 13 months, with a median interval of only three months between the initial reported reaction and the first allergy clinic assessment.
Supporting Data and Safety Concerns
One of the most critical aspects of the study was its transparent reporting of safety data. Because oral food challenges involve deliberately exposing a child to an allergen, there are inherent risks.
The study recorded 61 cases of anaphylaxis during 778 threshold OFCs, representing a 7.8% incidence rate. While this rate is higher than that observed in routine, non-infant allergy testing, the researchers argue that the risk is manageable and necessary.
"While these OFCs should be performed in centers with appropriate medical support, the trade-off is worthwhile," the research team concluded. The data indicated that while skin prick and blood tests were significantly linked to a positive OFC, they were poor predictors of the actual reaction threshold or the severity of a future reaction. This underscores a critical clinical gap: biomarkers can tell us if a child is sensitized to an allergen, but they cannot accurately predict if the child will react in a way that necessitates lifelong avoidance.
Implications for Clinical Practice
The findings of the ADAPT program are set to reshape pediatric allergy management. Currently, many clinicians avoid performing OFCs due to resource constraints, time limitations, or concerns about the safety of exposing an infant to an allergen.
Ending the "Avoidance Culture"
The study’s authors emphasize that misdiagnosis carries a heavy burden. Families living under the assumption that their child has a severe peanut allergy must deal with the constant stress of potential accidental exposure, the high cost of alternative food products, and the psychological impact of restrictive diets.
By confirming an allergy accurately, clinicians can:
- Prevent unnecessary avoidance: For the 34.8% who are not allergic, the burden of allergy is immediately lifted.
- Optimize Immunotherapy: For those who are truly allergic, an accurate threshold determination allows for more precise and safer OIT protocols.
- Improve Quality of Life: Reducing the incidence of "labeling" children who are actually tolerant improves the long-term psychosocial health of the family unit.
Official Responses and Future Directions
The medical community has reacted with significant interest to the publication in JACI: In Practice. Experts in the field of pediatric immunology have pointed out that the study provides a robust, evidence-based argument for why the "gold standard" of diagnosis must be more accessible.
"Biomarkers and clinical history alone are insufficient to diagnose peanut allergy in this age group," the researchers asserted. They advocate for a shift in policy where OFCs are considered a routine part of the evaluation process, regardless of whether the goal is to begin immunotherapy or to determine if the child can safely consume peanuts in their diet.
The ADAPT program’s success in standardizing care across 10 hospitals serves as a blueprint for other nations. By centralizing protocols and emphasizing the necessity of the OFC, healthcare systems can move toward a more diagnostic-driven approach rather than one based on anecdotal history and preliminary blood work.
Looking Ahead
As the researchers look to the future, they highlight that the ability to reintroduce peanuts early—for those who are found to be non-allergic—may fundamentally change the trajectory of food allergy development in childhood. Rather than waiting for children to potentially "outgrow" an allergy (a process that happens for only about 25–33% of children by age 6), clinicians can proactively clear those who were never truly allergic, thereby reducing the overall prevalence of the condition in the pediatric population.
In conclusion, the study is a call to action for pediatricians worldwide. The era of relying solely on a parent’s report of a reaction and a single blood test must come to an end. By embracing the rigor of the oral food challenge, the medical community can ensure that no child lives under the shadow of a food allergy they do not actually have.
